Seaport Therapeutics Reports Third-Quarter 2026 Financial Results
Seaport Therapeutics reported third-quarter 2026 financial results and highlighted recent corporate and clinical progress. The supplied body fragment says it announced positive topline data from a Phase 1 driving simulation trial of GlyphAllo.
Story updates
12:05:25 PM UTC
SquawkNews
Seaport reported first-patient dosing in its GlyphAgo Phase 2a trial and said GlyphAllo did not impair next-morning driving performance in a Phase 1 trial. BUOY-1 enrollment is on track, with topline data expected in 1H 2027.Material DetailsContext by AI AnalystSeaport is advancing two Phase 2 prog…